Lung Cell Study After Chest Radiation
Part of Cancer, Injuries & trauma, Lungs & breathing clinical trials.
This study looks at cells from the lungs of people who developed lung inflammation after chest radiation for cancer. It aims to understand why some people get this reaction, which may help find better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have received radiation therapy to your chest and have symptoms of radiation pneumonitis (shortness of breath, cough, chest discomfort starting 1 to 4 months after treatment).
- You need to be able to walk around, not need extra oxygen, and have oxygen levels above 92%.
- You must be willing to undergo a bronchoscopy (a procedure where a thin tube is placed into your lungs to collect cells) and be able to lie flat.
- You cannot have had COVID-19 in the last 6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at ways to predict who will develop radiation pneumonitis (lung inflammation after radiation) and how outcomes vary. It may help doctors better watch and treat lung side effects after lung cancer radiation.
This trial tests whether breathing in steroid medicine before and during radiation can lower how often and how badly “radiation lung inflammation” (radiation pneumonitis) happens in people with lung cancer. If you qualify, it may help protect your lungs while you receive radiation with chemotherapy or targeted therapy.
This Phase 1/2 study uses detailed “single-cell” testing (from lung samples) to better understand why lung inflammation happens after cancer radiation or immunotherapy. It aims to help choose the right treatment approach for people with radiation pneumonitis or immune checkpoint inhibitor pneumonitis.
This study tests whether adding radiation to the chest area can improve the effectiveness of maintenance immunotherapy (atezolizumab) in patients with extensive-stage small cell lung cancer who have responded well to initial treatment.
This study tries to find early warning markers in lung fluid collected during a bronchoscopy (a camera test of the airways). The goal is to better spot and understand lung inflammation that can happen after immune checkpoint cancer treatments.
This study monitors how the heart and lungs respond to radiation therapy combined with immunotherapy for locally advanced lung cancer. It aims to learn how well patients tolerate treatment and to detect early signs of side effects.
Hear when a new Radiation Pneumonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.